VNDA
$8.60
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic ...
Recent News
Why Vanda Pharmaceuticals (VNDA) Is Up 17.4% After Rare FDA Hearing Granted On HETLIOZ Jet Lag
Vanda Pharmaceuticals announced that the FDA has granted its request for a rare formal evidentiary public hearing to review CDER’s proposal to refuse approval of the supplemental new drug application for HETLIOZ (tasimelteon) in jet lag disorder, following a prior court ruling that criticized the agency’s handling of Vanda’s clinical evidence. This hearing, reportedly the first of its kind in decades for a drug approval dispute, highlights unusually intense legal and scientific scrutiny...
Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley
B. Riley raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $17 from $14 and keeps a Buy rating on the shares. Following BYSANTI’s approval, the firm’s revenue model for Vanda has been updated, reflecting expected growth in the psychiatry franchise with peak BYSANTI sales now included and probability adjustments removed, the analyst tells investors in a research note. Base assumptions include mid-to-high single-digit quarter over quarter growth in BYSANTI/FANAPT prescriptions thro
Novo to cut GLP-1 drug prices; Palvella soars on study data
Wegovy and Ozempic’s list prices will be reduced by as much as 50% effective next year. Elsewhere, Palvella’s market value surged past $1 billion while Pfizer nabbed rights to another obesity drug.
Trending tickers: Rolls-Royce, Fresnillo, JD Sports, Vanda Pharmaceuticals and IDFC First Bank
The latest investor updates on stocks that are trending on Monday.
Vanda Pharmaceuticals stock surges after the FDA approves its new Bipolar I drug
Investing.com – Vanda Pharmaceuticals (NASDAQ: VNDA) just announced that it has received FDA-approval for its new drug known as BYSANTI. The drug is meant to treat Bipolar I manic episodes as well as Schizophrenia symptoms in adults.